Taken together, modulation of AKT during TIL's rapid expansion stage might contribute to a better clinical outcome, which would be especially meaningful for ovarian or cervical cancer that generally have a lower response rate of TIL‐based therapy compared to melanoma. Here, AKT1 is linked to cervical carcinoma.